Preeclampsia Is a Double-Hit Vascular Disorder: The VEGF-HO-1-CSE Axis
Preprint
- 4 February 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Preeclampsia is a double-hit vascular disorder centred on the VEGF-HO-1-CSE axis. First, excess placental soluble Flt-1 (sFlt-1) neutralises vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), producing an angiogenic deficit that drives endothelial dysfunction, hypertension, proteinuria and end-organ injury. Second, failure of endogenous vascular brakes, heme oxygenase-1 (HO-1/CO) and cystathionine-γ-lyase (CSE)/hydrogen sulfide (H2S), amplifies anti-angiogenic factor release (sFlt-1, soluble endoglin) and oxidative-inflammatory stress, lowering the threshold at which VEGF loss precipitates severe disease. We synthesise human, animal and translational data that (i) establish placental sFlt-1 source and release, (ii) demonstrate human mechanistic causality via sFlt-1 removal, (iii) show prospective clinical validation that sFlt-1 rises and free PlGF falls before disease onset, and (iv) identify HO-1 and CSE/H2S as protective pathways that restrain anti-angiogenic drive. Finally, we summarise preclinical evidence that the oral H2S-donor MZe786 restores the HO-1/CSE axis, lowers sFlt-1, improves maternal haemodynamics and fetal outcomes across complementary pregnancy models, and outline the role of sFlt-1/PlGF-based triage (PROGNOSIS) in clinical decision-making. This reactive tool, while valuable, cannot sub-stratify among positive cases. Framing severe preeclampsia as a double-hit vascular disorder provides a biologically grounded framework that can inform risk stratification strategies like M-PREG®, a clinical decision support system, and prevention strategies, pairing early risk stratification with mechanism-informed interventions.Keywords
All Related Versions
- Version 1, 2026-02-04, Preprints
- Published version: Biomolecules, 16 (3), 436.
This publication has 35 references indexed in Scilit:
- HMOX1 Genetic Polymorphisms Display Ancestral Diversity and May Be Linked to Hypertensive Disorders in PregnancyReproductive Sciences, 2022
- Hydrogen sulfide releasing molecule MZe786 inhibits soluble Flt-1 and prevents preeclampsia in a refined RUPP mouse modelRedox Biology, 2021
- MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environmentRedox Biology, 2021
- Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trialThe Lancet, 2019
- Soluble fms‐like tyrosine kinase‐1 to placental growth factor ratio: ruling out pre‐eclampsia for up to 4 weeks and value of retestingUltrasound in Obstetrics & Gynecology, 2019
- Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factorsAmerican Journal of Obstetrics and Gynecology, 2016
- New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complicationsThrombosis Research, 2011
- Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia developAmerican Journal of Obstetrics and Gynecology, 2004
- Induction of Placental Heme Oxygenase-1 Is Protective Against TNFα-induced Cytotoxicity and Promotes Vessel RelaxationMolecular Medicine, 2000
- Heparin-binding angiogenic growth factors in pregnancyPlacenta, 1997